Armistice Capital
INM icon

Armistice Capital’s InMed Pharmaceuticals INM Stock Holding History

Armistice Capital’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,335
Closed -$97.2K – 321
2024
Q1 		$97.2K Buy
1,335
+305
+30% +$22.4K ﹤0.01% 307
2023
Q4 		$85.7K Buy
+1,030
New +$100K ﹤0.01% 259
2023
Q1 		– Sell
-486
Closed -$196K – 241
2022
Q4 		$196K Buy
486
+36
+8% +$24.2K ﹤0.01% 155
2022
Q3 		$593K Buy
450
+259
+136% +$479K 0.01% 147
2022
Q2 		$450K Buy
+191
New +$731K 0.01% 138
2021
Q4 		– Sell
-102
Closed -$893K – 159
2021
Q3 		$893K Sell
102
-76
-43% -$906K 0.02% 123
2021
Q2 		$2.83M Buy
178
+131
+279% +$2.03M 0.05% 102
2021
Q1 		$776K Buy
+47
New +$1.01M 0.02% 104

Other funds holding INM

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
AllSquare Wealth Management
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Armistice Capital's INM Position: Q2 2024 in Review

Armistice Capital sold out of InMed Pharmaceuticals (INM) in Q2 2024, closing a stake of 1,335 shares — an estimated $97.2K sold.

Armistice Capital first reported a position in INM in Q1 2021 and held it in 8 quarters. The position peaked at $2.83M in Q2 2021. 7 funds tracked by Wall St. Rank hold INM as of Q2 2024.

  • Armistice Capital reported no remaining InMed Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Armistice Capital sold 1,335 InMed Pharmaceuticals shares in Q2 2024, an estimated $97.2K.
  • Armistice Capital first reported a position in InMed Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Armistice Capital's InMed Pharmaceuticals position peaked at $2.83M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2024.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.